Improvement of cardiac fibrosis in dystrophic mice by rAAV9-mediated microdystrophin transduction

Gene Therapy

Volumn 18, Issue 9, 2011, Pages 910-919

  Shin, J H ^a   Nitahara Kasahara, Y ^a   Hayashita Kinoh, H ^a   Ohshima Hosoyama, S ^a   Kinoshita, K ^a   Chiyo, T ^a   Okada, H ^a   Okada, T ^a   Takeda, S ^a  

^a NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

AAV vector; cardiac fibrosis; cardiomyopathy; Duchenne muscular dystrophy; electrocardiography; microdystrophin

Indexed keywords

DYSTROPHIN;

ADENO ASSOCIATED VIRUS; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE CONDUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QRS COMPLEX;

AGING; ANIMALS; CARDIOMYOPATHIES; DEPENDOVIRUS; DYSTROPHIN; FIBROSIS; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, INBRED MDX; MUSCULAR DYSTROPHY, DUCHENNE; MYOCARDIUM; TRANSDUCTION, GENETIC; TRANSGENES;

ADENO-ASSOCIATED VIRUS; MUS;

EID: 80052594894     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.36     Document Type: Article

References (43)

1. Emery AE. Population frequencies of inherited neuromuscular diseases-a world survey. Neuromuscul Disord 1991; 1: 19-29.
2. Aartsma-Rus A, Van Deutekom JCT, Fokkema IF, Van Ommen G-JB, Den Dunnen JT. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 2006; 34: 135-144. (Pubitemid 44167796)
3. Bushby K, Muntoni F, Bourke JP. 107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands. Neuromuscul Disord 2003; 13: 166-172. (Pubitemid 36140013)
4. Moxley RT. Clinical overview of Duchenne muscular dystrophy. In: Chamberlain J, Rando T (eds). Duchenne Muscular Dystrophy: Advances in Therapeutics. Taylor & Francis Group: New York, 2006, pp 1-20.
5. Nigro G, Comi LI, Politano L, Nigro G. Cardiomyopathies associated with muscular dystrophies. In: Engel A, Franzini-Armstrong C (eds). Myology: Basic and Clinical. McGraw-Hill: New York, 2004, pp 1239-1256.
6. Connuck DM, Sleeper LA, Colan SD, Cox GF, Towbin JA, Lowe AM et al. Characteristics and outcomes of cardiomyopathy in children with Duchenne or Becker muscular dystrophy: a comparative study from the Pediatric Cardiomyopathy Registry. Am Heart J 2008; 155: 998-1005.
7. Gray SJ, Samulski RJ. Optimizing gene delivery vectors for the treatment of heart disease. Expert Opin Biol Ther 2008; 8: 911-922. (Pubitemid 352007003)
8. Hoffman EP, Brown RH, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919-928.
9. Dong JY, Fan PD, Frizzell RA. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Therapy 1996; 7: 2101-2112. (Pubitemid 26400735)
10. Yuasa K, Miyagoe Y, Yamamoto K, Nabeshima Y, Dickson G, Takeda S. Effective restoration of dystrophin-associated proteins in vivo by adenovirus-mediated transfer of truncated dystrophin cDNAs. FEBS Lett 1998; 425: 329-336. (Pubitemid 28178916)
11. Sakamoto M, Yuasa K, Yoshimura M, Yokota T, Ikemoto T, Suzuki M et al. Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem Biophys Res Commun 2002; 293: 1265-1272. (Pubitemid 34681078)
12. Yoshimura M, Sakamoto M, Ikemoto M, Mochizuki Y, Yuasa K, Miyagoe-Suzuki Y et al. AAV vector-mediated microdystrophin expression in a relatively small percentage of mdx myofibers improved the mdx phenotype. Mol Ther 2004; 10: 821-828. (Pubitemid 39419909)
13. Gregorevic P, Allen JM, Minami E, Blankinship MJ, Haraguchi M, Meuse L et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 2006; 12: 787-789. (Pubitemid 44050067)
14. Ohshima S, Shin JH, Yuasa K, Nishiyama A, Kira J, Okada T et al. Transduction efficiency and immune response associated with the administration of AAV8 vector into dog skeletal muscle. Mol Ther 2009; 17: 73-80.
15. Inagaki K, Fuess S, Storm TA, Gibson GA, McTiernan CF, Kay MA et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 2006; 14: 45-53. (Pubitemid 43899488)
16. Bulfield G, Siller WG, Wight PA, Moore KJ. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA 1984; 81: 1189-1192. (Pubitemid 14171480)
17. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard PJ. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 1989; 244: 1578-1580. (Pubitemid 19189735)
18. Im WB, Phelps SF, Copen EH, Adams EG, Slightom JL, Chamberlain JS. Differential expression of dystrophin isoforms in strains of mdx mice with different mutations. Hum Mol Genet 1996; 5: 1149-1153. (Pubitemid 26318554)
19. Sapp JL, Bobet J, Howlett SE. Contractile properties of myocardium are altered in dystrophin-deficient mdx mice. J Neurol Sci 1996; 142: 17-24. (Pubitemid 26340403)
20. Bridges LR. The association of cardiac muscle necrosis and inflammation with the degenerative and persistent myopathy of MDX mice. J Neurol Sci 1986; 72: 147-157. (Pubitemid 16125194)
21. Bostick B, Yue Y, Lai Y, Long C, Li D, Duan D. Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice. Hum Gene Therapy 2008; 19: 851-856.
22. Townsend D, Blankinship MJ, Allen JM, Gregorevic P, Chamberlain JS, Metzger JM. Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Mol Ther 2007; 15: 1086-1092. (Pubitemid 46813611)
23. Chu V, Otero JM, Lopez O, Sullivan MF, Morgan JP, Amende I et al. Electrocardiographic findings in mdx mice: a cardiac phenotype of Duchenne muscular dystrophy. Muscle Nerve 2002; 26: 513-519.
24. Pacak CA, Mah CS, Thattaliyath BD, Conlon TJ, Lewis MA, Cloutier DE et al. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 2006; 99: e3-e9. (Pubitemid 44255502)
25. Janssen PML, Hiranandani N, Mays TA, Rafael-Fortney JA. Utrophin deficiency worsens cardiac contractile dysfunction present in dystrophin-deficient mdx mice. Am J Physiol Heart Circ Physiol 2005; 289: H2373-H2378. (Pubitemid 41698545)
26. Quinlan JG, Hahn HS, Wong BL, Lorenz JN, Wenisch AS, Levin LS. Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromuscul Disord 2004; 14: 491-496. (Pubitemid 39141704)
27. Yue Y, Skimming JW, Liu M, Strawn T, Duan D. Full-length dystrophin expression in half of the heart cells ameliorates beta-isoproterenol-induced cardiomyopathy in mdx mice. Hum Mol Genet 2004; 13: 1669-1675. (Pubitemid 39136722)
28. Mann DL. Heart failure and cor pulmonale. In: Fauci AS, Braunwald E, Kasper DL et al. (eds) Harrison's Principles of Internal Medicine. 17th edn. chapter 227. McGraw Hill: New York, 2008, pp 1443-1457.
29. Dunlap ME, Bibevski S, Rosenberry TL, Ernsberger P. Mechanisms of altered vagal control in heart failure: influence of muscarinic receptors and acetylcholinesterase activity. Am J Physiol Heart Circ Physiol 2003; 285: H1632-H1640. (Pubitemid 37169519)
30. Das G, Talmers FN, Weissler AM. New observations on the effects of atropine on the sinoatrial and atrioventricular nodes in man. Am J Cardiol 1975; 36: 281-285.
31. Benditt DG, Pritchett LC, Smith WM, Wallace AG, Gallagher JJ. Characteristics of atrioventricular conduction and the spectrum of arrhythmias in Lown-Ganong-Levine syndrome. Circulation 1978; 57: 454-465. (Pubitemid 8284521)
32. Ansong AK, Li JS, Nozik-Grayck E, Ing R, Kravitz RM, Idriss SF et al. Electrocardiographic response to enzyme replacement therapy for Pompe disease. Genet Med 2006; 8: 297-301. (Pubitemid 44297316)
33. Linhart A, Lubanda JC, Palecek T, Bultas J, Karetová D, Ledvinová J et al. Cardiac manifestations in Fabry disease. J Inherit Metab Dis 2001; 24(Suppl 2): 75-83. (Pubitemid 33061636)
34. Kashani A, Barold SS. Significance of QRS complex duration in patients with heart failure. J Am Coll Cardiol 2005; 46: 2183-2192. (Pubitemid 41785483)
35. Bia BL, Cassidy PJ, Young ME, Rafael JA, Leighton B, Davies KE et al. Decreased myocardial nNOS, increased iNOS and abnormal ECGs in mouse models of Duchenne muscular dystrophy. J Mol Cell Cardiol 1999; 31: 1857-1862. (Pubitemid 29458703)
36. Frankel KA, Rosser RJ. The pathology of the heart in progressive muscular dystrophy: epimyocardial fibrosis. Hum Pathol 1976; 7: 375-386.
37. Yuasa K, Sakamoto M, Miyagoe-Suzuki Y, Tanouchi A, Yamamoto H, Li J et al. Adenoassociated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product. Gene Therapy 2002; 9: 1576-1588. (Pubitemid 35414520)
38. Lin J, Zhi Y, Mays L, Wilson JM. Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice. J Virol 2007; 81: 11840-11849. (Pubitemid 47623816)
39. Matsushita T, Elliger S, Elliger C, Podsakoff G, Villarreal L, Kurtzman GJ et al. Adenoassociated virus vectors can be efficiently produced without helper virus. Gene Therapy 1998; 5: 938-945. (Pubitemid 28371911)
40. Okada T, Nomoto T, Yoshioka T, Nonaka-Sarukawa M, Ito T, Ogura T et al. Large-scale production of recombinant viruses by use of a large culture vessel with active gassing. Hum Gene Ther 2005; 16: 1212-1218. (Pubitemid 41443713)
41. Okada T, Nonaka-Sarukawa M, Uchibori R, Kinoshita K, Hayashita-Kinoh H, Nitahara-Kasahara Y et al. Scalable purification of adeno-associated virus serotype 1 (AAV1) and AAV8 vectors, using dual ion-exchange adsorptive membranes. Hum Gene Ther 2009; 20: 1013-1021.
42. Pruitt KD, Tatusova T, Klimke W, Maglott DR. NCBI reference sequences: current status, policy and new initiatives. Nucleic Acids Res 2009; 37: D32-D36.
43. Fayssoil A. Tissue Doppler characterization of cardiac phenotype in mouse. Eur J Radiol 2009; 72: 82-84.